---
title: "Retatrutide FDA Approval Timeline: When Will Retatrutide Be Available?"
description: "Retatrutide FDA approval timeline: Phase 3 TRIUMPH status, TRIUMPH-4 results (-28.7% weight loss), NDA filing late 2026, and availability projections for 2027-2028."
url: https://retatrutide.med/blog/retatrutide-approval-timeline
date: 2025-11-05
lastUpdated: 2026-05-26
author: "retatrutide.med Editorial"
category: "regulatory"
tags: ["FDA approval", "regulatory", "NDA", "timeline", "Eli Lilly", "drug development", "TRIUMPH", "TRIUMPH-1", "TRIUMPH-4", "TRANSCEND-T2D-1", "Phase 3", "retatrutide approval date", "when will retatrutide be available"]
source: retatrutide.med
sourceType: "blog post"
license: CC-BY-NC-SA-4.0
canonical: https://retatrutide.med/blog/retatrutide-approval-timeline
---
## Where Retatrutide Stands Today (May 2026)

Retatrutide (LY3437943) is currently in late-stage Phase 3 clinical development under Eli Lilly's TRIUMPH program. **It is not approved for any indication in any country.** No New Drug Application (NDA) has been filed with the FDA or any other regulatory authority.

Three positive pivotal Phase 3 readouts are now in hand:

- **TRIUMPH-4** (December 2025) — first readout: -28.7% mean body weight reduction at 12 mg over 68 weeks in 445 adults with obesity and knee osteoarthritis, plus a 75.8% WOMAC pain reduction at 9 mg.
- **TRANSCEND-T2D-1** (April 30, 2026, reported in Eli Lilly's Q1 2026 earnings release) — first Phase 3 type 2 diabetes data: HbA1c reductions of 1.7-2.0 percentage points and weight loss of 11.1-16.6 kg across doses.
- **TRIUMPH-1** (May 21, 2026) — the pivotal obesity trial in 2,339 adults without diabetes: -28.3% at 12 mg/80 weeks (efficacy estimand), with 45.3% of 12 mg participants achieving ≥30% weight loss and the 104-week extension reaching -30.3% in the BMI ≥35 subgroup.

The drug completed Phase 2 trials with results published in the New England Journal of Medicine, demonstrating up to 24.2% body weight reduction at 48 weeks. The Phase 3 results to date have validated and exceeded those signals. Understanding when approval might occur requires examining the regulatory pathway step by step, without overstating the certainty of any timeline.

## The TRIUMPH Phase 3 Program

### Program Scope

Eli Lilly's Phase 3 program for retatrutide is one of the largest metabolic drug development programs currently underway. It includes:

- **TRIUMPH-1 through TRIUMPH-4**: Four pivotal trials evaluating retatrutide for obesity and weight-related conditions across different populations and comorbidities. TRIUMPH-1 and TRIUMPH-4 have reported. TRIUMPH-2 (obesity + T2D) is expected in Q2-Q3 2026 and TRIUMPH-3 (obesity + CVD) in Q3-Q4 2026.
- **TRIUMPH-Outcomes**: A separate ~10,000-patient cardiovascular outcomes trial (CVOT) with MACE as primary endpoint
- **TRANSCEND**: Type 2 diabetes program (TRANSCEND-T2D-1 reported April 2026; TRANSCEND-T2D-2 head-to-head vs semaglutide and TRANSCEND-CKD ongoing)
- **SYNERGY / MACELD**: Trials evaluating retatrutide for metabolic dysfunction-associated steatohepatitis (MASH), with histological endpoints

The program spans multiple countries, enrolls thousands of participants, and evaluates retatrutide across the full spectrum of metabolic disease — obesity, diabetes, and liver disease.

### TRIUMPH-4: First Phase 3 Results

TRIUMPH-4 was specifically designed for adults with obesity and knee osteoarthritis. Key results announced in December 2025:

- **Retatrutide 12 mg: -28.7% mean weight loss** at 68 weeks
- **Retatrutide 9 mg: -26.4% mean weight loss** at 68 weeks
- **99% of participants at 12 mg achieved at least 5% weight loss**
- **75% reduction in knee osteoarthritis pain scores** (WOMAC)
- **New safety signal: dysesthesia** (abnormal sensory sensations) in 20.9% at 12 mg versus 0.7% placebo

These results validated the Phase 2 signal and provided strong efficacy evidence for regulatory submission. However, TRIUMPH-4 alone is unlikely to be sufficient for an NDA — the FDA typically requires data from multiple pivotal trials, and the dysesthesia signal will need characterization across the broader program.

### Remaining Trial Readouts

As of May 2026, the following major readouts are still pending:

- **TRIUMPH-2** (obesity + type 2 diabetes, nested OSA basket): Expected Q2-Q3 2026
- **TRIUMPH-3** (obesity + established cardiovascular disease): Expected Q3-Q4 2026
- **TRANSCEND-T2D-2** (head-to-head vs semaglutide in T2D): Ongoing
- **TRANSCEND-CKD** (T2D + chronic kidney disease): Ongoing
- **SYNERGY / MACELD** (MASH, histological endpoints): Multi-year duration
- **TRIUMPH-Outcomes** (cardiovascular outcomes trial): Multi-year event-driven trial; post-approval timeline

Eli Lilly maintained NDA filing guidance of late 2026 to Q1 2027 at the Q1 2026 earnings call (April 30, 2026), confirming the company believes the package will be ready following the TRIUMPH-2 and TRIUMPH-3 readouts.

## The Regulatory Pathway: Step by Step

Drug approval follows a well-established sequence, each step with its own typical duration:

### Step 1: Phase 3 Data Collection and Readout (Current Stage)

Pivotal trials typically run 68-72 weeks for obesity indications. Including enrollment time, data collection, and analysis, the interval from Phase 3 initiation to primary data readout is generally 2-3 years. TRIUMPH-4 has reported, and initial results from other TRIUMPH trials are anticipated in late 2026 to 2027.

### Step 2: NDA Preparation and Submission

After positive Phase 3 results, the sponsor compiles the complete data package into a New Drug Application. This process typically takes 6-12 months after the primary data readout, though some sponsors begin preparing the NDA in parallel with late-stage data collection (a strategy called "rolling submission").

For the obesity indication, Eli Lilly will need to compile data from TRIUMPH-4 and at least one additional pivotal obesity trial, along with the complete safety database from across the TRIUMPH program. NDA filing is expected in **late 2026**, based on Eli Lilly's Q4 2025 earnings guidance (February 4, 2026).

### Step 3: FDA Review

Once an NDA is accepted for review, the FDA standard review period is 10-12 months. Priority Review designation, if granted, shortens this to approximately 6-8 months.

- **Standard Review**: 10-12 months from NDA acceptance
- **Priority Review**: 6-8 months from NDA acceptance

Priority Review is granted when a drug offers a significant improvement over available therapy for a serious condition. Given the magnitude of retatrutide's weight loss and the potential MASLD benefit, Priority Review is plausible but not guaranteed.

### Step 4: Advisory Committee Meeting

The FDA may convene an advisory committee (AdCom) of independent experts to evaluate the application. This is not always required but is common for novel mechanisms. The advisory committee reviews efficacy data, safety concerns (including the dysesthesia signal), and the overall benefit-risk profile. The AdCom provides a recommendation, but the FDA is not bound by it.

### Step 5: FDA Decision (PDUFA Date)

The FDA sets a target action date (the PDUFA date) when it commits to completing its review. The agency will either approve the drug, issue a Complete Response Letter requesting additional information, or (rarely) deny approval outright.

## Realistic Timeline Estimates

### Optimistic Scenario (Mid-2027)

This scenario assumes:
- NDA submitted in late 2026, per Eli Lilly's Q4 2025 earnings guidance
- Priority Review designation is granted (6-8 month review)
- No major safety signals beyond dysesthesia, which is adequately characterized
- Clean FDA review with no major information requests

### Base Case Scenario (Late 2027 - Early 2028)

This is the most likely timeline:
- NDA submitted in late 2026
- Standard or Priority Review (10-12 months or 6-8 months)
- FDA approval in **late 2027 to early 2028**

### Delayed Scenario (2028 or Later)

Possible if:
- Dysesthesia signal requires additional safety studies
- FDA requests a cardiovascular outcomes trial before approval
- Manufacturing or supply chain issues delay submission
- Enrollment delays push trial readouts later than expected

## How This Compares to Tirzepatide and Semaglutide

Examining the timelines of recently approved metabolic drugs provides useful context:

### Semaglutide (Wegovy)

Novo Nordisk published the STEP 1 Phase 3 obesity results in February 2021. The FDA approved Wegovy in June 2021 — an unusually fast turnaround enabled by prior approval of semaglutide for diabetes (Ozempic) and rolling NDA submission. The total development time from first-in-human to obesity approval was approximately 6 years.

### Tirzepatide (Zepbound)

Eli Lilly published the SURMOUNT-1 Phase 3 obesity data in mid-2022. Zepbound received FDA approval for obesity in November 2023, approximately 17 months later. This was expedited by prior diabetes approval (Mounjaro in May 2022), which established the safety database and manufacturing infrastructure.

### Retatrutide: Key Difference

A critical difference for retatrutide is that **it does not yet have approval in any indication**. Without a prior diabetes approval to build upon, the first retatrutide approval may take somewhat longer than the obesity approvals for semaglutide and tirzepatide. The FDA will need to evaluate the entire safety database from scratch, including the novel glucagon receptor component and the dysesthesia signal.

## Potential for Expedited Pathways

Several factors could accelerate retatrutide's path:

- **Breakthrough Therapy Designation**: If the FDA determines that retatrutide may offer substantial improvement over existing treatments, this designation provides more intensive FDA guidance, organizational commitment, and potentially faster review. The -28.7% weight loss in TRIUMPH-4 and the unique triple receptor mechanism could support such a designation.
- **Rolling submission**: Eli Lilly could submit sections of the NDA as they are completed rather than waiting for the complete package, reducing the gap between data readout and submission acceptance.
- **Priority Review**: Possible given the significant unmet need, particularly for MASLD where approved treatments are limited.
- **Accelerated Approval** (for MASH): If SYNERGY demonstrates histological improvement, an accelerated approval pathway for the MASH indication could be explored, though this would likely be separate from the obesity filing.

## Multiple Indications, Multiple Timelines

Different indications will likely follow different regulatory timelines:

- **Obesity**: Most likely the first indication, given commercial precedent and regulatory familiarity with weight management approvals. Estimated approval: mid-2027 to early 2028, based on NDA filing expected in late 2026.
- **Type 2 diabetes**: Could follow closely after the obesity approval, using the TRANSCEND data. Estimated approval: late 2027-2028.
- **MASH**: May require longer trials with histological endpoints and faces a less established regulatory pathway. The SYNERGY trial could support approval, but timing depends on study duration and regulatory requirements. Estimated approval: 2029 or later.

## Latest Milestones as of May 2026

| Date | Milestone |
|---|---|
| Mid-2022 | Phase 2 obesity results published (NEJM) |
| Late 2022 | Phase 2 type 2 diabetes results published (Lancet) |
| 2023 | Phase 3 TRIUMPH program initiated |
| December 2025 | TRIUMPH-4 results announced (-28.7% weight loss, 75.8% WOMAC pain reduction) |
| April 30, 2026 | TRANSCEND-T2D-1 results in Q1 earnings (HbA1c -1.7 to -2.0 pp, weight -11.1 to -16.6 kg) |
| May 21, 2026 | TRIUMPH-1 results announced (-28.3% at 12 mg/80 weeks, 45.3% achieving ≥30% loss) |
| Q2-Q3 2026 | TRIUMPH-2 readout expected (obesity + T2D) |
| Q3-Q4 2026 | TRIUMPH-3 readout expected (obesity + CVD) |
| Late 2026 - Q1 2027 | NDA submission expected |

## What Needs to Happen Before Approval

For patients wondering "when will retatrutide be available," here is what must still occur:

1. **Remaining Phase 3 trials must report results**: TRIUMPH-4 alone is not sufficient for an NDA. At minimum, the primary obesity pivotal trial must be completed.
2. **Safety database must be compiled**: The FDA requires a comprehensive safety analysis across all trials.
3. **Dysesthesia must be characterized**: The 20.9% incidence in TRIUMPH-4 needs context from other trials.
4. **NDA must be prepared and submitted**: This includes manufacturing data, labeling proposals, and the complete clinical dataset.
5. **FDA must complete its review**: 6-12 months depending on review pathway.
6. **Manufacturing must be scaled**: Commercial-scale production of retatrutide must be established and validated.

## Frequently Asked Questions About Retatrutide Approval

### When will retatrutide be approved?

The most realistic estimate for FDA approval is **late 2027 to early 2028**, with an optimistic scenario of mid-2027 if Priority Review is granted. Eli Lilly indicated during its Q4 2025 earnings call (February 4, 2026) that NDA filing is expected in late 2026. The timeline is subject to change.

### Has Eli Lilly filed for FDA approval of retatrutide?

No. As of May 2026, no NDA or BLA has been filed with the FDA for retatrutide. Three pivotal Phase 3 readouts are in hand (TRIUMPH-4, TRANSCEND-T2D-1, and TRIUMPH-1), and TRIUMPH-2 plus TRIUMPH-3 are expected to read out in the second half of 2026. Eli Lilly continues to guide toward NDA filing in late 2026 to Q1 2027.

### Will retatrutide get Priority Review from the FDA?

It is possible but not guaranteed. Priority Review is granted when a drug offers significant improvement over available therapy for a serious condition. Retatrutide's -28.7% weight loss in TRIUMPH-4 and its unique triple receptor mechanism could support a Priority Review designation, which would shorten the FDA review period from 10-12 months to 6-8 months.

### Can I get retatrutide through a clinical trial?

Yes, clinical trial enrollment is the only legitimate way to access retatrutide. Visit ClinicalTrials.gov and search for "retatrutide" or "LY3437943" to find active trials. Eligibility criteria vary by trial, and participants may be randomized to placebo.

### Why is drug approval so slow?

The FDA approval process is designed to ensure that medications are both safe and effective before being made available to the public. Phase 3 trials must enroll thousands of participants, treat them for extended periods (often 68+ weeks), collect and analyze data, and demonstrate an acceptable benefit-risk profile. This process protects patients but inherently takes time — typically 2-3 years for Phase 3 alone, followed by 6-12 months of FDA review.

## What Patients and Clinicians Should Know

The most important message is that **retatrutide is not yet available and will not be for at least 1-2 years**. Patients should:

- Work with their healthcare providers on currently approved treatment options (Wegovy, Zepbound, etc.)
- Not purchase unregulated "retatrutide" from online sources — these products are not FDA-approved, not quality-controlled, and potentially dangerous
- Consider clinical trial enrollment as the only legitimate route to access retatrutide, via ClinicalTrials.gov
- Monitor Eli Lilly's public announcements for Phase 3 data updates

Timelines in drug development are inherently uncertain. The estimates provided here are based on typical regulatory patterns and publicly available information, but actual events may diverge significantly in either direction.

## Key Takeaways

- **Current status**: Retatrutide is in Phase 3 (TRIUMPH program), with TRIUMPH-4 topline results announced in December 2025
- **Not approved**: No regulatory authority has approved retatrutide for any indication
- **No NDA filed**: Eli Lilly has not yet submitted a regulatory application
- **TRIUMPH-4 results**: -28.7% weight loss at 12 mg, the largest ever in a Phase 3 obesity trial
- **Remaining steps**: Additional Phase 3 readouts, NDA preparation, FDA review, and potential advisory committee
- **NDA filing**: Expected late 2026 (per Eli Lilly Q4 2025 earnings guidance)
- **Best estimate for approval**: Late 2027 - early 2028 (base case), mid-2027 (optimistic)
- **How to access now**: Clinical trials only, via ClinicalTrials.gov
- **Warning**: Avoid unregulated online sources claiming to sell retatrutide